New metabolic drug SNS851 gets first human safety check
NCT ID NCT07417124
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study is testing a new drug, SNS851, in 52 healthy adults to see if it is safe and how the body processes it. Participants will receive either the drug or a placebo by injection. The goal is to check for side effects, not to treat any disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Veritus Research
RECRUITINGMelbourne, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Eating within a 10-hour window may shield breast cancer patients from heart-harming fat buildup
- La reunion health survey aims to uncover hidden disease patterns
- Could a traditional Plant-Based diet curb diabetes risk in latino communities?
- Half-Matched stem cell transplant offers hope for children with rare immune and metabolic diseases
- Exercise rewires fat tissue at the cellular level, study hints
- Can a smartphone app lift the emotional burden of type 2 diabetes?